

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 June 2023 (08.06.2023)



(10) International Publication Number
WO 2023/102225 A3

(51) International Patent Classification:

C12N 15/113 (2010.01) A61P 25/16 (2006.01)
A61K 31/7125 (2006.01) A61P 25/28 (2006.01)

(21) International Application Number:

PCT/US2022/051713

(22) International Filing Date:

02 December 2022 (02.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/285,786 03 December 2021 (03.12.2021) US
63/350,206 08 June 2022 (08.06.2022) US
63/398,987 18 August 2022 (18.08.2022) US

(71) Applicant: **QURALIS CORPORATION** [US/US]; 100
Cambridgepark Drive, Suite 500, Cambridge, Massachu-
setts 02140 (US).

(72) Inventors; and

(71) Applicants: **HINCKLEY, Sandra** [US/US]; c/o Quralis
Corporation, 100 Cambridgepark Drive, Suite 500, Cam-
bridge, Massachusetts 02140 (US). **BROWN, Duncan**
[US/US]; 1490 Arch Street, Berkeley, California 94708
(US). **ELBAUM, Daniel** [US/US]; c/o Quralis Corporation,
100 Cambridgepark Drive, Suite 500, Cambridge, Massa-
chusetts 02140 (US).

(72) Inventor: **KAMELGARN, Marisa Elizabeth**; c/o Quralis
Corporation, 100 Cambridgepark Drive, Suite 500, Cam-
bridge, Massachusetts 02140 (US).

(74) Agent: **ZHANG, Clark et al.**; Goodwin Procter LLP, 100
Northern Avenue/IP Docketing 7th fl, Boston, Massachu-
setts 02210 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(88) Date of publication of the international search report:

28 March 2024 (28.03.2024)

(54) Title: TREATMENT OF NEUROLOGICAL DISEASES USING MODULATORS OF UNC13A GENE TRANSCRIPTS




FIGURE 1

(57) Abstract: Disclosed herein are UNC13A oligonucleotides with one or more spacers or without a spacer. In various embodiments, UNC13A oligonucleotides with spacer(s) reduce mis-spliced UNC13A transcripts and increase full length UNC13A transcripts, thereby imparting therapeutic efficacy against neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or Alzheimer's disease (AD).

WO 2023/102225 A3